Palo Alto-based Spot Biosystems has emerged from stealth with USD 40 million in venture financing and early clinical data suggesting its extracellular vesicle (EV) platform can deliver full-length dystrophin gene to human skeletal muscle — a milestone that has eluded the gene therapy field and that underpins the company's case for a non-viral alternative to adeno-associated virus approaches in Duchenne muscular dystrophy (DMD).
Investors backing the round include LDV Partners, IDG Capital, Advantech Capital, Tiger Jade Capital, Shanda Ventures, the Stanford StartX Fund, and Saltagen Ventures. No single lead investor was designated. The company said proceeds will support its ongoing investigator-initiated trial (IIT) and inform a future US regulatory pathway.
Spot Biosystems' platform, grounded in research conducted at Stanford University School of Medicine, Ohio State University, and MD Anderson Cancer Center, encapsulates large nucleic acid cargo — including full-length dystrophin mRNA — inside engineered extracellular vesicles delivered intravenously to skeletal muscle. Unlike AAV-based approaches, which are constrained by a packaging capacity of approximately 4.7 kilobases and are generally limited to a single lifetime dose due to anti-capsid immune responses, EV-based delivery is non-viral, supports repeat dosing, and can accommodate the full-length dystrophin construct, which at approximately 14 kilobases far exceeds AAV capacity.
Preclinical findings published in Nature Biomedical Engineering reported that EV-delivered dystrophin mRNA produced sustained protein expression and improved muscle strength, endurance, and motor function in DMD knockout mice. In non-human primates, repeated intravenous dosing resulted in sustained dystrophin expression without liver, kidney, or cardiac toxicity — a safety profile that contrasts with adverse events reported in some AAV-based programs.
Based on these data, Spot Biosystems launched an IIT at Shanghai Children's Medical Center. The company said the first two pediatric DMD patients dosed demonstrated a respective 1,000%+ and 2,000%+ increase in dystrophin after one month of dosing, with functional muscle improvement reported for up to six months after dosing cessation. These findings are preliminary and based on a first-in-human cohort of two patients; the study investigators said they will continue to assess drug response and safety in larger patient populations with extended treatment duration.